{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"* Complete response rate (CRR) will be defined as the proportion of evaluable patients meeting the criteria complete (CR) or stringent complete response (sCR)\n* Stringent complete response (sCR) requires all of the following:\n\n  * CR as defined below\n  * Normal free light chain ratio (0.26-1.65)\n  * Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence\n* Complete response (CR) requires all of the following:\n\n  * Disappearance of monoclonal protein by both protein electrophoresis and immunofixation studies from the blood and urine\n  * If serum and urine monoclonal protein are unmeasurable, Normal free light chain ratio (0.26-1.65)\n  * \\<5% plasma cells in the bone marrow\n  * Disappearance of soft tissue plasmacytoma\n* Patients who do not meet the definition of CR based solely on residual monoclonal protein on serum electrophoresis and/or immunofixation, but are MRD-negative as described above, will also be considered CR.","groups":[{"description":"* Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study.\n* Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol.\n* Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT:\n\n  * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+\n  * 2 mg pomalidomide daily on Days 1-21 of all cycles\n  * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+\n* Continuation therapy may continue until relapse or progression.","id":"OG000","title":"Elotuzumab + Pomalidomide + Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only 18 patients were evaluable for this outcome measure. 6 patients did not have ASCT and 1 patient had ASCT but did not start continuation treatment.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Complete Response Rate (CRR)","type":"SECONDARY","unitOfMeasure":"Participants"}